IMRX
Immuneering Corporation5.74
-0.04-0.69%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
370.63MP/E (TTM)
-Basic EPS (TTM)
-1.79Dividend Yield
0%Recent Filings
10-K
FY2025 results
Immuneering reported FY2025 ended December 31, 2025, with ongoing clinical losses typical for a late-stage biotech lacking approved products or revenue. Q4 momentum shone in the Phase 2a trial of atebimetinib plus mGnP in first-line pancreatic cancer, showing 64% OS at 12 months (median follow-up 13.4 months) and median PFS of 8.5 months in 34 patients, trouncing standard-of-care benchmarks from the MPACT trial. No revenue, but cash burn funds MAPKeeper 301 Phase 3 launch mid-2026. Envometinib paused. Q4 data builds trial momentum. Clinical delays threaten timelines.
8-K
64% survival beats benchmark
Immuneering reported 64% 12-month overall survival in its Phase 2a trial of atebimetinib + mGnP for first-line pancreatic cancer, crushing the 35% GnP standard. Cash hit $217M, funding ops into 2029 while prepping Phase 3 MAPKeeper 301 launch mid-2026. Pipeline advances fast. No head-to-head data yet.
8-K
Stronger survival data
Immuneering announced updated Phase 2a data on January 7, 2026, showing 64% 12-month overall survival in 34 first-line pancreatic cancer patients on 320mg atebimetinib plus mGnP—doubling the standard 35% from MPACT trial—with median PFS at 8.5 months and median OS unreached after 13.4 months follow-up. Safety remains solid: anemia and neutropenia hit 18% Grade ≥3, no deaths. Upcoming milestones include Phase 3 start mid-2026. Cross-trial comparisons demand caution.
10-Q
Q3 FY2025 results
Immuneering narrowed Q3 operating losses to $15.4M from $15.3M y/y (derived), with R&D dipping 3.4% to $10.9M as atebimetinib expenses rose 10.9% y/y while IMM-6-415 fell 75.8% after pausing advancement. Net loss improved to $15.0M or $(0.38) diluted EPS from $14.6M or $(0.49), reconciling to 39.7M weighted shares. Cash swelled to $227.6M from $36.1M y/e 2024, fueled by $164.1M public offering, $25.0M Aventis private placement (closed Sep 2025), and $23.4M August private placement (all stock), funding into 2029. No debt; leases only. Steady burn. Competition shadows atebimetinib's path.
8-K
86% survival, $225M raised
ALT
Altimmune, Inc.
5.03-0.25
CUE
Cue Biopharma, Inc.
0.41-0.05
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNM
Immunome, Inc.
23.48+0.84
IMTX
Immatics N.V.
10.09+0.11
IMUX
Immunic, Inc.
0.60-0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
TIL
Instil Bio, Inc.
11.25+0.13